Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAWH Ascend Wellness	$0.31 +6.0%	$0.34	$0.27 ▼ $1.23	$63.38M	1.03	117,140 shs	62,357 shs
AUTL Autolus Therapeutics	$2.31 -0.4%	$1.71	$1.11 ▼ $5.00	$617.45M	1.76	1.57 million shs	1.33 million shs
ORIC Oric Pharmaceuticals	$10.50 +2.6%	$7.05	$3.90 ▼ $14.67	$871.84M	1.49	789,974 shs	1.74 million shs
TKNO Alpha Teknova	$5.11 -1.5%	$6.06	$1.16 ▼ $10.37	$277.36M	0.4	412,396 shs	275,071 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAWH Ascend Wellness	+6.86%	+6.90%	+0.78%	-16.19%	-67.37%
AUTL Autolus Therapeutics	-0.43%	+12.14%	+47.13%	+39.16%	-31.25%
ORIC Oric Pharmaceuticals	+2.64%	+13.88%	+81.66%	+71.01%	+58.37%
TKNO Alpha Teknova	-1.54%	-7.26%	-12.95%	-1.92%	+296.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAWH Ascend Wellness	0.5779 of 5 stars	0.0	3.0	0.0	0.0	1.7	1.3
AUTL Autolus Therapeutics	2.6475 of 5 stars	3.5	1.0	0.0	2.7	3.3	0.6
ORIC Oric Pharmaceuticals	4.0637 of 5 stars	3.5	0.0	4.3	2.7	3.3	0.6
TKNO Alpha Teknova	2.8598 of 5 stars	3.5	3.0	0.0	3.8	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAWH Ascend Wellness	4.00	Strong Buy	N/A	N/A
AUTL Autolus Therapeutics	3.00	Buy	$9.32	303.46% Upside
ORIC Oric Pharmaceuticals	3.00	Buy	$19.17	82.54% Upside
TKNO Alpha Teknova	3.00	Buy	$8.50	66.34% Upside

Current Analyst Ratings Breakdown

Latest AAWH, ORIC, AUTL, and TKNO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	ORIC Oric Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/29/2025	ORIC Oric Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
5/6/2025	ORIC Oric Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $12.00
5/6/2025	ORIC Oric Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/5/2025	ORIC Oric Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $21.00
4/10/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/1/2025	AUTL Autolus Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAWH Ascend Wellness	$518.59M	0.12	$0.05 per share	6.64	$0.69 per share	0.45
AUTL Autolus Therapeutics	$10.12M	60.75	N/A	N/A	$1.61 per share	1.43
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.45 per share	N/A
TKNO Alpha Teknova	$37.74M	7.24	N/A	N/A	$1.55 per share	3.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAWH Ascend Wellness	-$48.21M	-$0.40	N/A	N/A	N/A	-15.47%	-72.18%	-9.55%	N/A
AUTL Autolus Therapeutics	-$220.66M	-$0.88	N/A	N/A	N/A	N/A	-52.82%	-29.67%	8/8/2025 (Estimated)
ORIC Oric Pharmaceuticals	-$127.85M	-$1.87	N/A	N/A	N/A	N/A	-51.14%	-46.29%	8/11/2025 (Estimated)
TKNO Alpha Teknova	-$26.75M	-$0.48	N/A	N/A	N/A	-60.90%	-28.48%	-19.73%	8/12/2025 (Estimated)

Latest AAWH, ORIC, AUTL, and TKNO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million
5/8/2025	Q1 2025	TKNO Alpha Teknova	-$0.11	-$0.09	+$0.02	-$0.09	$9.41 million	$9.60 million
5/5/2025	Q1 2025	ORIC Oric Pharmaceuticals	-$0.51	-$0.42	+$0.09	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAWH Ascend Wellness	N/A	N/A	N/A	N/A	N/A
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TKNO Alpha Teknova	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAWH Ascend Wellness	2.61	1.47	0.80
AUTL Autolus Therapeutics	N/A	9.24	9.02
ORIC Oric Pharmaceuticals	N/A	12.00	12.00
TKNO Alpha Teknova	0.17	5.64	4.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAWH Ascend Wellness	17.31%
AUTL Autolus Therapeutics	72.83%
ORIC Oric Pharmaceuticals	95.05%
TKNO Alpha Teknova	13.81%

Insider Ownership

Company	Insider Ownership
AAWH Ascend Wellness	22.08%
AUTL Autolus Therapeutics	25.70%
ORIC Oric Pharmaceuticals	6.82%
TKNO Alpha Teknova	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAWH Ascend Wellness	2,300	204.44 million	166.44 million	Not Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
ORIC Oric Pharmaceuticals	80	85.22 million	79.41 million	Optionable
TKNO Alpha Teknova	240	53.44 million	46.76 million	Not Optionable

AAWH, ORIC, AUTL, and TKNO Headlines

Recent News About These Companies

Conestoga Capital Advisors LLC Sells 52,070 Shares of Alpha Teknova, Inc. (NASDAQ:TKNO)

June 17, 2025 | marketbeat.com

61,811 Shares in Alpha Teknova, Inc. (NASDAQ:TKNO) Acquired by Jane Street Group LLC

May 31, 2025 | marketbeat.com

Alpha Teknova, Inc. (NASDAQ:TKNO) Q1 2025 Earnings Call Transcript

May 10, 2025 | msn.com

Alpha Teknova, Inc. (TKNO) Q1 2025 Earnings Call Transcript

May 10, 2025 | seekingalpha.com

Teknova Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Alpha Teknova (TKNO) Traded Lower on Increased Uncertainty

April 30, 2025 | msn.com

Alpha Teknova, Inc. to Report First Quarter Financial Results on May 8, 2025

April 24, 2025 | quiverquant.comQ

Teknova to Report First Quarter 2025 Financial Results on May 8, 2025

April 24, 2025 | globenewswire.com

Alpha Teknova, Pluristyx launch proprietary PluriFreeze cryopreservation system

March 20, 2025 | markets.businessinsider.com

Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies

March 19, 2025 | markets.businessinsider.com

Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies

March 19, 2025 | globenewswire.com

Teknova, Pluristyx announce collaboration over next-generation cell therapies

March 11, 2025 | markets.businessinsider.com

Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies

March 11, 2025 | globenewswire.com

Earnings Update: Here's Why Analysts Just Lifted Their Alpha Teknova, Inc. (NASDAQ:TKNO) Price Target To US$10.67

March 8, 2025 | uk.finance.yahoo.com

BTIG Reaffirms Their Hold Rating on Alpha Teknova (TKNO)

March 6, 2025 | markets.businessinsider.com

Alpha Teknova, Inc. (NASDAQ:TKNO) Q4 2024 Earnings Call Transcript

March 6, 2025 | msn.com

Alpha Teknova’s Earnings Call: Growth Amid Challenges

March 5, 2025 | tipranks.com

Alpha Teknova, Inc. (TKNO) Q4 2024 Earnings Call Transcript

March 4, 2025 | seekingalpha.com

Alpha Teknova Reports Steady Revenue Growth in 2024

March 4, 2025 | tipranks.com

Alpha Teknova reports Q4 EPS (11c) vs. (26c) last year

March 4, 2025 | markets.businessinsider.com

Alpha Teknova sees FY25 revenue f $39M -$42M, consensus $41.75M

March 4, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback Stock
By Leo Miller | June 9, 2025
View In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback Stock

AAWH, ORIC, AUTL, and TKNO Company Descriptions

Ascend Wellness OTC:AAWH

$0.31 +0.02 (+5.98%)

As of 06/26/2025 03:47 PM Eastern

Ascend Wellness Holdings, Inc. engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the United States. The company offers flower, pre-rolls, concentrates, vapes, edibles, tinctures, and other cannabis-related products under the Common Goods, SimplyHerb, Ozone, Ozone Reserve, Royale, Tunnel Vision, Miss Grass, Lowell Smokes, Edie Parker, 1906, and AiroPro brands. It also owns, operates, and manages cannabis cultivation facilities and dispensaries. The company sells its products through company-owned retail stores and third-party licensed retail cannabis stores. Ascend Wellness Holdings, Inc. was incorporated in 2018 and is headquartered in New York, New York.

Autolus Therapeutics NASDAQ:AUTL

$2.31 -0.01 (-0.43%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$2.30 -0.01 (-0.61%)

As of 04:00 AM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Oric Pharmaceuticals NASDAQ:ORIC

$10.50 +0.27 (+2.64%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$10.46 -0.04 (-0.43%)

As of 04:47 AM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Alpha Teknova NASDAQ:TKNO

$5.11 -0.08 (-1.54%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$5.10 -0.02 (-0.29%)

As of 06/26/2025 04:04 PM Eastern

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time